WO2004044226A3 - Induction of cellular senescence by cdk4 disruption for tumor supression and regression - Google Patents

Induction of cellular senescence by cdk4 disruption for tumor supression and regression Download PDF

Info

Publication number
WO2004044226A3
WO2004044226A3 PCT/US2003/036037 US0336037W WO2004044226A3 WO 2004044226 A3 WO2004044226 A3 WO 2004044226A3 US 0336037 W US0336037 W US 0336037W WO 2004044226 A3 WO2004044226 A3 WO 2004044226A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdk4
disruption
regression
induction
cellular senescence
Prior art date
Application number
PCT/US2003/036037
Other languages
French (fr)
Other versions
WO2004044226A2 (en
Inventor
Hiroaki Kiyokawa
Xianghong Zou
Original Assignee
Univ Illinois
Hiroaki Kiyokawa
Xianghong Zou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Hiroaki Kiyokawa, Xianghong Zou filed Critical Univ Illinois
Priority to AU2003287692A priority Critical patent/AU2003287692A1/en
Publication of WO2004044226A2 publication Critical patent/WO2004044226A2/en
Publication of WO2004044226A3 publication Critical patent/WO2004044226A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Abstract

The invention provides methods of inhibiting growth of tumor cells comprising contacting the cells with a Cdk4 inhibitor. The invention also provides methods of treating patients having, suspected of having, or at a high risk for developing, a cancer, comprising treatment with a Cdk4 inhibitor. The invention also relates to pharmaceutical compositions for treating such patients, wherein the pharmaceutical compositions comprise a Cdk4 inhibitor.
PCT/US2003/036037 2002-11-12 2003-11-12 Induction of cellular senescence by cdk4 disruption for tumor supression and regression WO2004044226A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287692A AU2003287692A1 (en) 2002-11-12 2003-11-12 Induction of cellular senescence by cdk4 disruption for tumor supression and regression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42537202P 2002-11-12 2002-11-12
US60/425,372 2002-11-12

Publications (2)

Publication Number Publication Date
WO2004044226A2 WO2004044226A2 (en) 2004-05-27
WO2004044226A3 true WO2004044226A3 (en) 2005-02-17

Family

ID=32312979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036037 WO2004044226A2 (en) 2002-11-12 2003-11-12 Induction of cellular senescence by cdk4 disruption for tumor supression and regression

Country Status (2)

Country Link
AU (1) AU2003287692A1 (en)
WO (1) WO2004044226A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20010047019A1 (en) * 2000-02-07 2001-11-29 Salvati Mark E. 3-Aminopyrazole inhibitors of cyclin dependent kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20010047019A1 (en) * 2000-02-07 2001-11-29 Salvati Mark E. 3-Aminopyrazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
AU2003287692A1 (en) 2004-06-03
WO2004044226A2 (en) 2004-05-27
AU2003287692A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
PT1297851E (en) INHIBITION OF HISTONE-DESACETILASE AS TREATMENT FOR CARDIAC HYPERTROPHY
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003039460A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
NO20070514L (en) Pyrrolotriazine kinase inhibitors
NO20060398L (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for the treatment and inhibition of cancer
WO2003079973A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2004058700A3 (en) Mitotic kinesin inhibitors
MX2008015775A (en) Compounds and compositions for treatment of cancer.
TR200401316T4 (en) Compounds and methods for treating proliferative diseases
WO2005118592A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2006078598A3 (en) Mitotic kinesin inhibitors
WO2005060960A3 (en) Use of histamine to treat bone disease
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2005060654A3 (en) Mitotic kinesin inhibitors
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP